
IMHOTEP, PJP, and more
May 14, 2026 - 00:09:59
Radio and PodcastLive Radio & Podcasts
Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce. Also, a 10-year follow-up study of ibrutinib provides big pictu...
Relacorilant is an episode from OncoPharm by OncoPharmPod. Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce. Also, a 10-year follow-u...
This episode belongs to OncoPharm.
Use the player on this page to stream the episode online.
Published Apr 9, 2026, 00:15:13 long, audio available.
Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce. Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: Check out the Oncology Insights Newsletter:
You can listen to Relacorilant online on Radio and Podcast. Open the player on this page to stream the available audio.
Relacorilant is an episode from OncoPharm by OncoPharmPod.
This episode is 00:15:13 long.
This episode was published on Apr 9, 2026.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from OncoPharm when more episodes are available from the podcast feed.